Journal Title：Expert Review Of Clinical Pharmacology

Advances in drug development technologies are yielding innovative new therapies, from potentially lifesaving medicines to lifestyle products. In recent years, however, the cost of developing new drugs has soared, and concerns over drug resistance and pharmacoeconomics have come to the fore. Adverse reactions experienced at the clinical trial level serve as a constant reminder of the importance of rigorous safety and toxicity testing. Furthermore the advent of pharmacogenomics and ‘individualized’ approaches to therapy will demand a fresh approach to drug evaluation and healthcare delivery.

Clinical Pharmacology provides an essential role in integrating the expertise of all of the specialists and players who are active in meeting such challenges in modern biomedical practice.

藥物開(kāi)發(fā)技術(shù)的進(jìn)步正在催生創(chuàng)新的新療法，從可能挽救生命的藥物到生活方式產(chǎn)品。然而，近年來(lái)，開(kāi)發(fā)新藥的成本飆升，對(duì)耐藥性和藥物經(jīng)濟(jì)學(xué)的擔(dān)憂也日益凸顯。臨床試驗(yàn)階段的不良反應(yīng)不斷提醒人們嚴(yán)格的安全性和毒性測(cè)試的重要性。此外，藥物基因組學(xué)和“個(gè)性化”治療方法的出現(xiàn)將要求一種新的藥物評(píng)估和醫(yī)療保健方法。

臨床藥理學(xué)在整合所有積極應(yīng)對(duì)現(xiàn)代生物醫(yī)學(xué)實(shí)踐中此類挑戰(zhàn)的專家和參與者的專業(yè)知識(shí)方面發(fā)揮著重要作用。

Expert Review Of Clinical Pharmacology創(chuàng)刊于2008年，由Taylor and Francis Ltd.出版商出版，收稿方向涵蓋PHARMACOLOGY & PHARMACY全領(lǐng)域，此刊是中等級(jí)別的SCI期刊，所以過(guò)審相對(duì)來(lái)講不是特別難，但是該刊專業(yè)認(rèn)可度不錯(cuò)，仍然是一本值得選擇的SCI期刊 。平均審稿速度 ，影響因子指數(shù)3.6，該期刊近期沒(méi)有被列入國(guó)際期刊預(yù)警名單，廣大學(xué)者值得一試。